Recipharm

Recipharm AB operates as a pharmaceutical contract development and manufacturing company. Its dosage forms include solid dose, steriles, semi solids, beta-lactams, hormones, dry powder inhalers, granulates, and powders. The company provides pharmaceutical development services, such as formulation development, clinical supplies, analytical development, stability studies, packaging development and selection, and raw material selection; and manufacturing services. It also offers EU gateway release and testing, regulatory, stability studies, and customized services. Recipharm AB was founded in 1995 and is based in Haninge, Sweden. It has manufacturing facilities in Sweden, France, and the United Kingdom.

Type
Public
HQ
Stockholm, SE
Size (employees)
2,638 (est)
Recipharm is headquartered in Stockholm, SE

Key People at Recipharm

Thomas Eldered

Thomas Eldered

CEO
Sture Nordberg

Sture Nordberg

Vice President of Science & Technology

Recipharm Office Locations

Recipharm has office in Stockholm
Stockholm, SE

Recipharm Metrics

Recipharm Financials

Recipharm's revenue is kr3.55 B in FY, 2015 which is 31.87% increase from the previous period.
FY, 2015FY, 2014

Revenue

kr3.55 Bkr2.69 B

Revenue growth, %

22.0%

Cost of goods sold

kr959 Mkr704 M

Gross profit

kr2.59 Bkr1.99 B

Gross profit Margin, %

73.0%73.8%

Sales and marketing expense

kr800 Mkr589 M

General and administrative expense

kr1.18 Bkr889 M

Operating expense total

kr2.04 Bkr1.51 B

Depreciation and amortization

kr236 Mkr127 M

EBITDA

kr510 Mkr399 M

EBITDA margin, %

14.4%14.8%

EBIT

kr274 Mkr272 M

EBIT margin, %

7.7%10.1%

Interest expense

kr29 Mkr65.4 M

Interest income

kr64.4 Mkr9.3 M

Income tax expense

kr94.6 Mkr55.9 M

Pre tax profit

kr310 Mkr216 M

Net Income

kr215 Mkr160 M

Operating cash flow

kr429 Mkr254 M

Recipharm Revenue Breakdown

Recipharm Company Life